The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
The INK4 family of cell cycle inhibitors in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862 · cited 1×
“CDK4 and CDK6 are cyclin D-dependent kinases whose primary substrate is pRB (Sherr, 1994; Weinberg, 1995).”
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 2×
“Since the discovery of p16INK4a (Serrano et al., 1993) and p21CIP1 (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993), the cyclin-dependent kinase inhibitors (CKIs) have been intensively investigated.”
Backgroundp21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Self-citationNakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., & Nakayama, K.-I. (1996) · Cell · doi:10.1016/s0092-8674(00)81237-4 · Cited by 1,547
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“…of CDK4 and CDK6, and thus prevents pRB phosphorylation and exit from the G1 phase, p19ARF does not bind to CDKs, but rather interacts with mdm2, and arrests cells in G1 and G2 phases (Kamijo et al., 1998; Pomerantz et al., 1998; Zhang et al., 1998; Weber et al., 1999; Zhang and Xiong, 1999).”
BackgroundOuelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L.-H., Broudy, V., Perlmutter, R. M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81239-8 · Cited by 1,457
Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27
Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., & Koff, A. (1996) · Cell · doi:10.1016/s0092-8674(00)81238-6 · Cited by 1,251
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
Self-citationA p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Nucleolar Arf sequesters Mdm2 and activates p53
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940
Self-citationp14ARF links the tumour suppressors RB and p53
Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., & Vousden, K. H. (1998) · Nature · doi:10.1038/25867 · Cited by 918 · cited 2×
“Recently, hyperproliferative signals emanating from oncogenes, including myc (Zindy et al., 1998), E1A (De Stanchina et al., 1998), E2F1 (Bates et al., 1998), and ras V12 (Zindy et al., 1998), have been identi®ed as potent inducers of p19ARF, suggesting that p19ARF acts as a sensor of growth signals to induce p53, cel…”
BackgroundThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Self-citationRetinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
Diehl, J. A., Zindy, F., & Sherr, C. J. (1997) · Genes & Development · doi:10.1101/gad.11.8.957 · Cited by 746 · cited 1×
“In this scenario, CDK4 is redistributed from cyclin D-CDK4 complexes to INK4-CDK4 complexes, and unbound Dtype cyclin is rapidly degraded by the ubiquitindependent proteasome degradation pathway (Diehl et al., 1997).”
BackgroundPavletich, N. P. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2640 · Cited by 744
Regulation of p16 CDKN2 Expression and Its Implications for Cell Immortalization and Senescence
Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.859 · Cited by 733
Tumor surveillance via the ARF–p53 pathway
Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.19.2984 · Cited by 717
Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Hirai, H., Roussel, M. F., Kato, J.-Y., Ashmun, R. A., & Sherr, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2672 · Cited by 646
Self-citationE1A signaling to p53 involves the p19ARFtumor suppressor
de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 609
Self-citationZindy, F., Quelle, D. E., Roussel, M. F., & Sherr, C. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201178 · Cited by 574
Self-citationP19 ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
Tao, W., & Levine, A. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6937 · Cited by 540
The INK4A/ARF locus and its two gene products.
Sharpless, N. E., & DePinho, R. A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80004-5 · Cited by 533 · cited 1×
“Several excellent reviews on CKIs (Harper and Elledge, 1996; Nakayama and Nakayama, 1998) and the roles of p16INK4a (Ruas and Peters, 1998) and the INK4a/ARF locus in cancer have been recently published (Sherr, 1998; Sharpless and DePinho, 1999).”
BackgroundRusso, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt, E., Ichimura, K., Reifenberger, G., & Collins, V. P. (1994) · PubMed · Cited by 508
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483 · cited 2×
“In proliferating cells, three di erent CDK4 complexes exist: (1) a 450-kDa complex composed of CDK4 or CDK6, and HSP90/CDC37; (2) a 150 ± 170-kDa complex composed of cyclin D, CDK4 or CDK6, and p27KIP1 or p21CIP1; and (3) a 50- kDa complex composed of CDK4 or CDK6 and INK4 proteins (Mahony et al., 1998; McConnell et a…”
BackgroundGrowth suppression by p16ink4 requires functional retinoblastoma protein
Medema, R. H., Herrera, R. E., Lam, F., & Weinberg, R. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6289 · Cited by 433
Drexler, H. (1998) · Leukemia · doi:10.1038/sj.leu.2401043 · Cited by 426
Role of the cyclin-dependent kinase inhibitors in the development of cancer
Hirama, T., & Koeffler, H. (1995) · Blood · doi:10.1182/blood.v86.3.841.841 · Cited by 418
Franklin, D. S., Godfrey, V. L., Lee, H., Kovalev, G. I., Schoonhoven, R., Chen-Kiang, S., Su, L., & Xiong, Y. (1998) · Genes & Development · doi:10.1101/gad.12.18.2899 · Cited by 412
Cdk inhibitors in development and cancer
Wade Harper, J., & Elledge, S. J. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90011-8 · Cited by 399
Complex structure and regulation of the P16 (MTS1) locus.
Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H. L., Parry, D., Peters, G., & Kamb, A. (1995) · PubMed · Cited by 383
Identification of Human and Mouse p19, a Novel CDK4 and CDK6 Inhibitor with Homology to p16ink4
Chan, F. K. M., Zhang, J., Cheng, L., Shapiro, D. N., & Winoto, A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2682 · Cited by 339
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., & Frants, R. R. (1995) · Nature Genetics · doi:10.1038/ng0795-351 · Cited by 310
The cell cycle and the retinoblastoma protein family
Ewen, M. E. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00690418 · Cited by 303
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280 · cited 1×
“These mutations prevent p16INK4a from binding CDK4 (Ranade et al., 1995; Koh et al., 1995; Yang et al., 1995; Arap et al., 1997).”
BackgroundMcConnell, B. B., Gregory, F. J., Stott, F. J., Hara, E., & Peters, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1981 · Cited by 238 · cited 1×
“…di erent CDK4 complexes exist: (1) a 450-kDa complex composed of CDK4 or CDK6, and HSP90/CDC37; (2) a 150 ± 170-kDa complex composed of cyclin D, CDK4 or CDK6, and p27KIP1 or p21CIP1; and (3) a 50- kDa complex composed of CDK4 or CDK6 and INK4 proteins (Mahony et al., 1998; McConnell et al., 1999).”
BackgroundBrotherton, D. H., Dhanaraj, V., Wick, S., Brizuela, L., Domaille, P. J., Volyanik, E., Xu, X., Parisini, E., Smith, B. O., Archer, S. J., et al. (1998) · Nature · doi:10.1038/26164 · Cited by 210 · cited 1×
“Recent NMR and crystallography studies of the structures of p16INK4a and p19INK4d in complex with CDK6 (Russo et al., 1998; Brotherton et al., 1998), and of p18INK4c (Venkataramani et al., 1998; Li et al., 1999) con®rmed that all INK4-proteins have similar structures (Pavletich, 1999).”
BackgroundCip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development
Nakayama, K.-I., & Nakayama, K. (1999) · BioEssays · doi:10.1002/(sici)1521-1878(199812)20:12<1020::aid-bies8>3.0.co;2-d · Cited by 205
FitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8541 · Cited by 200
Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia
Okuda, T., Shurtleff, S., Valentine, M., Raimondi, S., Head, D., Behm, F., Curcio- Brint, A., Liu, Q., Pui, C., & Sherr, C. (1995) · Blood · doi:10.1182/blood.v85.9.2321.bloodjournal8592321 · Cited by 192
Induction of Cell Cycle Arrest and B Cell Terminal Differentiation by CDK Inhibitor p18 and IL-6
Morse, L., Chen, D., Franklin, D., Xiong, Y., & Chen-Kiang, S. (1997) · Immunity · doi:10.1016/s1074-7613(00)80241-1 · Cited by 159
The ins and outs of RB: coupling gene expression to the cell cycle clock
Sherr, C. J. (1994) · Trends in Cell Biology · doi:10.1016/0962-8924(94)90033-7 · Cited by 159
Franklin, D. S., & Xiong, Y. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.10.1587 · Cited by 139
Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells
Mahony, D., Parry, D. A., & Lees, E. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201570 · Cited by 115
Washimi, O., Nagatake, M., Osada, H., Ueda, R., Koshikawa, T., Seki, T., Takahashi, T., & Takahashi, T. (1995) · PubMed · Cited by 114
Mutational effects on the p16INK4a tumor suppressor protein.
Yang, R., Gombart, A. F., Serrano, M., & Koeffler, H. P. (1995) · PubMed · Cited by 92
Interaction between Cdc37 and Cdk4 in human cells
Lamphere, L., Fiore, F., Xu, X., Brizuela, L., Keezer, S. M., Sardet, C., Draetta, G. F., & Gyuris, J. (1997) · Oncogene · doi:10.1038/sj.onc.1201036 · Cited by 92
Venkataramani, R. N., Swaminathan, K., & Marmorstein, R. (1998) · Nature Structural Biology · doi:10.1038/nsb0198-74 · Cited by 89
Adachi, M., Roussel, M. F., Havenith, K., & Sherr, C. J. (1997) · Blood · doi:10.1182/blood.v90.1.126 · Cited by 55
Self-citationThe p19INK4D Cyclin dependent kinase inhibitor gene is altered in osteosarcoma
Miller, C. W., Yeon, C., Aslo, A., Mendoza, S., Aytac, U., & Koeffler, H. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201185 · Cited by 35
Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human glioma
Arap, W., Knudsen, E. S., Wang, J. Y. J., Cavenee, W. K., & Huang, H.-J. S. (1997) · Oncogene · doi:10.1038/sj.onc.1200870 · Cited by 33
Cited by
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“That all four strains of Ink4 null mice are born at the expected Mendelian ratio and develop normally also implies that no one family member is essential for cell cycle control (Roussel, 1999; Ortega et al., 2002).”
BackgroundThe INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Non-Classical P38 Map Kinase Functions: Cell Cycle Checkpoints and Survival
Thornton, T. M., & Rincon, M. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.44 · Cited by 443
Klussmann, J. P., Gültekin, E., Weissenborn, S. J., Wieland, U., Dries, V., Dienes, H. P., Eckel, H. E., Pfister, H. J., & Fuchs, P. G. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63871-0 · Cited by 431
Metadata
- Authors
- Roussel, M. F.
- Venue
- Oncogene
- Published
- 1999-09-20
- Volume
- 18
- Issue
- 38
- Pages
- 5311-5317
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2014462533
- Cited by
- 322
- References
- 67
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.